AAI101 i.v.
Drug600 mg, 1 g, 2 g, 4 g, 1 g (every 6h), 2 g (every 6h)
Other names: AAI101
NCT Number: NCT03685084
* To assess the safety and tolerability of single and multiple ascending intravenous doses of AAI101 (SAD & MAD) in healthy male subjects. * To assess the safety and tolerability of single and multiple ascending intravenous doses of AAI101 in combination with fixed intravenous doses of piperacillin or cefepime in healthy male subjects
Looking for future studies?
Notify Me18 year–45 year
Male
Interventional
Phase 1
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Main Exclusion Criteria:
600 mg, 1 g, 2 g, 4 g, 1 g (every 6h), 2 g (every 6h)
Other names: AAI101
Vehicle infusion
Other names: Vehicle
piperacillin 3 g i.v.
Other names: Beta-lactam antibiotic
cefepime 1 g i.v.
Other names: Beta-lactam antibiotic
Time frame: Throughout the period that subjects receive study drug up to 5 days following discontinuation of study treatment
Safety will be evaluated from reported signs and symptoms and clinical laboratory tests
Time frame: Up to 24 hours post-dose
Cmax will be compared before and after administration of AAI101 either alone or in the presence of cefepime or piperacillin
Time frame: Up to 24 hours post-dose
Clast will be compared before and after administration of AAI101 either alone or in the presence of cefepime or piperacillin
Time frame: Up to 24 hours post-dose
AAI101 Urea Under the Curve will be compared before and after administration of AAI101 either alone or in the presence of cefepime or piperacillin
Time frame: Up to 24 hours post-dose
AAI101 t1/2 plasma pharmacokinetic parameter will be compared for AAI101 alone or in the presence of cefepime or piperacillin
Allecra
Industry
Phase I, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of AAI101 Administered Intravenously Alone or in Combination With Piperacillin or Cefepime to Healthy Adult Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details